Equity Profile

DCTH

Delcath Systems, Inc.

Health CareHealth Care Equipment$444.3M

May5Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Delcath Systems, Inc. is a healthcare company focused on developing innovative treatments for cancer....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and investors will be looking for signs of improvement or continued losses.

N/A

Revenue

While revenue estimates are not available, any reported figures will be crucial in assessing the company's market performance and growth potential.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DCTH Q2-2026 Earnings Preview

Context

Company Snapshot

Delcath Systems, Inc. is a healthcare company focused on developing innovative treatments for cancer. Operating in the health care equipment sector, it aims to improve patient outcomes through its specialized medical devices and therapies.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-19.79%

Avg Stock Reaction

+1.27%

Last Quarter Recap

In the last quarter, Delcath reported an EPS of -$0.03, missing the estimate of -$0.01. The stock reacted negatively, dropping 0.18% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Delcath's upcoming earnings are uncertain, with no analyst estimates available. Investors are keen to see if the company can turn around its recent performance.

Bull Case

If Delcath can report a smaller loss than expected or even a profit, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company reports a larger loss or disappointing revenue, it may lead to further declines in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be for Q2-2026?

This will be critical in determining whether the company is making progress towards profitability or continuing to struggle.

How much revenue did Delcath generate in the last quarter?

Revenue figures will provide insight into the company's market demand and overall health, influencing investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Delcath to narrow its losses this quarter, given recent operational adjustments.

Supporting Evidence

The options market is pricing a larger move than the stock has historically shown, indicating potential for a surprise.

Past performance shows that even minor improvements in EPS have led to significant stock reactions.

Key Risk

If the EPS loss is less than -$0.02, it could challenge the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching for signs of improvement in profitability and revenue generation.

Bull Confirmed If

Reporting an EPS loss of less than -$0.02 would confirm a positive trend.

Bear Confirmed If

An EPS loss greater than -$0.05 would indicate worsening financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±17.0%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings report.

Options are pricing ±17.0% while DCTH has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.1%

30d HV

42.6%

Calls (3K)P/C Ratio: 0.02Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Delcath beats expectations, history suggests a potential stock increase of around 6.09%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity.

Miss

A miss on earnings could lead to a decline of about 6.09%, reflecting ongoing concerns about the company's financial stability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new treatments or devices in the pipeline.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for Delcath's products.
4Details on partnerships or collaborations that could impact growth.
5Any guidance on future earnings expectations or strategic direction.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

DaVita Inc.

Company Snapshot

Delcath Systems, Inc. is a healthcare company focused on developing innovative treatments for cancer....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and investors will be looking for signs of improvement or continued losses.

N/A

Revenue

While revenue estimates are not available, any reported figures will be crucial in assessing the company's market performance and growth potential.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DCTH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-19.79%

Avg Stock Reaction

+1.27%

Last Quarter Recap

In the last quarter, Delcath reported an EPS of -$0.03, missing the estimate of -$0.01. The stock reacted negatively, dropping 0.18% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Delcath's upcoming earnings are uncertain, with no analyst estimates available. Investors are keen to see if the company can turn around its recent performance.

Bull Case

If Delcath can report a smaller loss than expected or even a profit, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company reports a larger loss or disappointing revenue, it may lead to further declines in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be for Q2-2026?

This will be critical in determining whether the company is making progress towards profitability or continuing to struggle.

How much revenue did Delcath generate in the last quarter?

Revenue figures will provide insight into the company's market demand and overall health, influencing investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Delcath to narrow its losses this quarter, given recent operational adjustments.

Supporting Evidence

The options market is pricing a larger move than the stock has historically shown, indicating potential for a surprise.

Past performance shows that even minor improvements in EPS have led to significant stock reactions.

Key Risk

If the EPS loss is less than -$0.02, it could challenge the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching for signs of improvement in profitability and revenue generation.

Bull Confirmed If

Reporting an EPS loss of less than -$0.02 would confirm a positive trend.

Bear Confirmed If

An EPS loss greater than -$0.05 would indicate worsening financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±17.0%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings report.

Options are pricing ±17.0% while DCTH has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.1%

30d HV

42.6%

Calls (3K)P/C Ratio: 0.02Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Delcath beats expectations, history suggests a potential stock increase of around 6.09%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity.

Miss

A miss on earnings could lead to a decline of about 6.09%, reflecting ongoing concerns about the company's financial stability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new treatments or devices in the pipeline.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for Delcath's products.
4Details on partnerships or collaborations that could impact growth.
5Any guidance on future earnings expectations or strategic direction.